

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-6</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,093,399	July 25, 2000	Thorpe <i>et al.</i>	424	182	
	A2	6,051,230	April 18, 2000	Thorpe <i>et al.</i>	424	178.1	
	A3	6,036,955	March 14, 2000	Thorpe <i>et al.</i>	424	136.1	
	A4	6,022,541	February 8, 2000	Senger <i>et al.</i>	424	172.1	
	A5	6,004,555	December 21, 1999	Thorpe <i>et al.</i>	424	181.1	
	A6	6,004,554	December 21, 1999	Thorpe <i>et al.</i>	424	178.1	
	A7	5,965,132	October 12, 1999	Thorpe <i>et al.</i>	424	149	
	A8	5,877,289	March 2, 1999	Thorpe <i>et al.</i>	530	387.1	
	A9	5,874,542	February 23, 1999	Rockwell <i>et al.</i>	530	387.3	
	A10	5,874,081	February 23, 1999	Parish	424	130.1	
	A11	5,866,127	February 2, 1999	Senger <i>et al.</i>	424	178.1	
	A12	5,863,538	January 26, 1999	Thorpe <i>et al.</i>	424	136.1	
	A13	5,855,866	January 5, 1999	Thorpe <i>et al.</i>	424	1.49	
	A14	5,854,205	December 29, 1998	O'Reilly <i>et al.</i>	514	2	
	A15	5,840,301	November 24, 1998	Rockwell <i>et al.</i>	424	143.1	
	A16	5,776,427	July 7, 1998	Thorpe <i>et al.</i>	424	1.49	
	A17	5,677,181	October 14, 1997	Parish	435	332	
	A18	5,660,827	August 26, 1997	Thorpe <i>et al.</i>	424	152.1	
	A19	5,659,013	August 19, 1997	Senger <i>et al.</i>	530	350	
	A20	5,587,297	December 24, 1996	Jacobson <i>et al.</i>	435	29	
	A21	5,569,786	October 29, 1996	Pettit <i>et al.</i>	568	646	
	A22	4,975,278	December 4, 1990	Senter <i>et al.</i>	424	94.3	
	A23	4,940,726	July 10, 1990	Pettit <i>et al.</i>	514	450	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. D cket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Thorpe and Brekken	
	Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-6</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	4,456,550	June 26, 1984	Dvorak <i>et al.</i>	260	112	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO99/40118	Aug. 12, 1999	PCT			
	B2	WO 98/45332	Oct. 15, 1998	PCT			
	B3	WO 98/45331	Oct. 15, 1998	PCT			
	B4	WO 96/01653	Jan. 25, 1996	PCT			
	B5	WO 93/17715	Sept. 16, 1993	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Akuzawa, <i>et al.</i> , "Zinc Finger Transcription Factor Egr-1 Activates Flt-1 Gene Expression in THP-1 Cells on Induction for Macrophage Differentiation", <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 20(2):377-84, 2000.
	C2	Asano, <i>et al.</i> , "Inhibition of Tumor Growth and Metastasis by an Immunoneutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor/Vascular Permeability Factor," <i>Cancer Res.</i> , 55:5296-5301, 1995.
	C3	Asano, <i>et al.</i> , "An Anti-human VEGF Monoclonal Antibody, MV833, that Exhibits Potent Anti-tumor Activity <i>in vivo</i> ," <i>Hybridoma</i> , 17:185-90, 1998.
	C4	Baca <i>et al.</i> , "Antibody Humanization using Monovalent Phage Display," <i>J. Biol. Chem.</i> , 272(16):10678-84, 1997.
	C5	Benjamin, <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C6	Borgstrom, <i>et al.</i> , "Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy," <i>Cancer Res.</i> , 56(17):4032-1439, 1996.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-6</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Borgstrom, <i>et al.</i> , "Neutralizing Anti-vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>in vivo</i> ," <i>Prostate</i> , 35(1):1-10, 1998.
	C8	Borgstrom, <i>et al.</i> , "Importance of VEGF for Breast Cancer Angiogenesis <i>in vivo</i> : Implications from Intravital Microscopy of Combination Treatments with an Anti-VEGF Neutralizing Monoclonal Antibody and Doxorubicin," <i>Anticancer Research</i> , 19(5B):4203-11, 1999.
	C9	Brekken, "Vascular Endothelial Growth Factor as a Target for the Therapy of Solid Tumors," <i>Ph.D. Dissertation, The University of Texas Southwestern Medical Center at Dallas</i> , February, 1999; Volume 60104-B of Dissertation Abstracts International, page 1385.
	C10	Brekken, <i>et al.</i> , "Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium," <i>Cancer Res.</i> , 58(9):1952-1959, 1998.
	C11	Burrows and Thorpe, "Vascular Targeting-a New Approach to the Therapy of Solid Tumors," <i>Pharmacol. Ther.</i> , 64:155-174, 1994.
	C12	Burrows <i>et al.</i> , "A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors," <i>Cancer Research</i> , 52:5954-5962, 1992.
	C13	Burrows and Thorpe, "Eradication of Large Solid Tumors in Mice with an Immunotoxin Directed Against Tumor Vasculature," <i>Proc. Natl. Acad. Sci. USA</i> , 90:8996-9000, 1993.
	C14	Claffey, <i>et al.</i> , "Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor by Melanoma Cells Increases Tumor Growth, Angiogenesis, and Experimental Metastasis," <i>Cancer Res.</i> , 56:172-181, 1996.
	C15	Clauss <i>et al.</i> , "The Vascular Endothelial Cell Growth Factor Receptor Flt-1 Mediates Biological Activities," <i>J. Biol. Chem.</i> , 271(30):17629-17634, 1996.
	C16	Davis and Yancopoulos, "The Angiopoietins: Yin and Yang in Angiogenesis," <i>Curr. Top. Microbiol. Immunol.</i> , 237:173-85, 1999.
	C17	Denekamp, "Vascular Attack as a Therapeutic Strategy for Cancer," <i>Cancer and Metastasis Reviews</i> , 9:267-282, 1990.
	C18	Dvorak <i>et al.</i> , "Structure of Solid Tumors and Their Vasculature: Implications for Therapy with Monoclonal Antibodies," <i>Cancer Cells</i> , 3:77-85, 1991.
	C19	Dvorak, <i>et al.</i> , "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors - Concentration in Tumor Blood Vessels," <i>J. Exp. Med.</i> , 174:1275-1278, 1991.
	C20	Fidler and Ellis, "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis [comment]," <i>Cell</i> , 79(2):185-188, 1994.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Thorpe and Brekken	
	Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-6</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Fong, <i>et al.</i> , "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," <i>Nature</i> , 376:66-70, 1995.
	C22	Gerber, <i>et al.</i> , "VEGF Couples Hypertrophic Cartilage Remodeling, Ossification and Angiogenesis During Endochondral Bone Formation"; <i>Nature Medicine</i> , 5(6):623-8, 1999.
	C23	Hagemeier <i>et al.</i> , "A Monoclonal Antibody Reacting with Endothelial Cells of Budding Vessels in Tumors and Inflammatory Tissues, and Non-Reactive with Normal Adult Tissues," <i>Int. J. Cancer</i> , 38:481-488, 1986.
	C24	Hanahan and Folkman, "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):353-364, 1996.
	C25	Hiratsuka, <i>et al.</i> , "Flt-1 Lacking the Tyrosine Kinase Domain is Sufficient for Normal Development and Angiogenesis in Mice," <i>Proc. Natl. Acad. Sci. USA</i> , 95(16):9349-9354, 1998.
	C26	Holash <i>et al.</i> , "Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF", <i>Science</i> , 284:1994-1998, 1999.
	C27	Huang <i>et al.</i> , "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> , 275:547-550, 1997.
	C28	Keyt <i>et al.</i> , "Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors. Generation of Receptor-Selective VEGF Variants by Site-Directed Mutagenesis," <i>J. Biol. Chem.</i> , 271(10):5638-46, 1996.
	C29	Kim, <i>et al.</i> , "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies," <i>Growth Factors</i> , 7:53-64, 1992.
	C30	Kim, <i>et al.</i> , "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth <i>in vivo</i> ," <i>Nature</i> , 362:841-844, 1993.
	C31	Kondo, <i>et al.</i> , "Significance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and its Inhibition by the Antibody," <i>Biochem. Biophys. Res. Commun.</i> , 194:1234-1241, 1993.
	C32	Koukourakis, <i>et al.</i> , "Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer," <i>Cancer Res.</i> , 60:3088-3095, 2000.
	C33	Kroll and Waltenberger, "The Vascular Endothelial Growth Factor Receptor KDR Activates Multiple Signal Transduction Pathways in Porcine Aortic Endothelial Cells", <i>J. Biol. Chem.</i> , 272:32521-7, 1997.
	C34	Lin, <i>et al.</i> , "Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor", <i>J. Pharmacol. Exp. Therap.</i> , 288(1):371-8, 1999.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Lin-Ke, <i>et al.</i> , "Vascular Targeting of Solid and Ascites Tumors with Antibodies to Vascular Endothelial Growth Factor," <i>Eur. J. Cancer</i> , 32A(14):2467-2473, 1996.
	C36	Luo, <i>et al.</i> , "Differential Inhibition of Fluid Accumulation and Tumor Growth in Two Mouse Ascites Tumors by an Antivascular Endothelial Growth Factor/Permeability Factor Neutralizing Antibody," <i>Cancer Res.</i> , 58(12):2594-2600, 1998.
	C37	Luo, <i>et al.</i> , "Significant Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Mouse Ascites Tumors," <i>Cancer Res.</i> , 58(12):2652-2660, 1998.
	C38	Mesiano, <i>et al.</i> , "Role of Vascular Endothelial Growth Factor in Ovarian Cancer: Inhibition of Ascites Formation by Immunoneutralization," <i>Am. J. Pathol.</i> , 153(4):1249-1256, 1998.
	C39	Mordenti, <i>et al.</i> , "Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans", <i>Toxicologic Pathology</i> , 27(1):14-21, 1999.
	C40	Muller, <i>et al.</i> , "VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface," <i>Structure</i> , 6(9):1153-67, 1998.
	C41	Mustonen and Alitalo, "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biol.</i> , 129:895-898, 1995.
	C42	Niida, <i>et al.</i> , "Vascular Endothelial Growth Factor can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption", <i>J. Exp. Med.</i> , 190(2):293-8, 1999.
	C43	Ohizumi <i>et al.</i> , "Antibody-Based Therapy Targeting Tumor Vascular Endothelial Cells Suppresses Solid Tumor Growth in Rats," <i>Biochem. Biophys. Res. Comm.</i> , 236:493-496, 1997.
	C44	Presta, <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and other Disorders," <i>Cancer Res.</i> , 57:4593-4599, 1997.
	C45	Ran <i>et al.</i> , "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Res.</i> , 58:4646-4653, 1998.
	C46	Ruf and Edgington, "Structural Biology of Tissue Factor, the Initiator of Thrombogenesis <i>in vivo</i> ," <i>FASEB J.</i> , 8: 385-390, 1994.
	C47	Ryan, <i>et al.</i> , "Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody", <i>Toxicologic Pathology</i> , 27(1):78-86, 1999.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1 and 2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-6</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C48	Schlaeppli and Wood, "Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-Tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-Kinase Inhibitors," <i>Cancer and Metastasis Rev.</i> , 18:473-481, 1999.
	C49	Shalaby, <i>et al.</i> , "Failure of Blood-Island Formation and Vasculogenesis in Flk-1-Deficient Mice," <i>Nature</i> , 376:62-66, 1995.
	C50	Siemeister, <i>et al.</i> , "The Pivotal Role of VEGF in Tumor Angiogenesis: Molecular Facts and Therapeutic Opportunities," <i>Cancer Metastasis Rev.</i> , 17(2):241-248, 1998.
	C51	Sioussat, <i>et al.</i> , "Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies," <i>Arch. Biochem. Biophys.</i> , 301:15-20, 1993.
	C52	Veikkola, <i>et al.</i> , "Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors," <i>Cancer Res.</i> , 60:203-212, 2000.
	C53	Waltenberger, <i>et al.</i> , "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> , 269(43):26988-26995, 1994.
	C54	Wiesmann, <i>et al.</i> , "Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor," <i>Cell</i> , 91(5):695-704, 1997.
	C55	Co-pending Application Serial No. 09/561,500; Entitled: "Antibody Compositions for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket Nos. 4001.002500).
	C56	Co-pending Application Serial No. 09/561,499; Entitled: "Antibody Methods for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket Nos. 4001.002582).
	C57	Co-pending Application Serial No. 09/562,245; Entitled: "Antibody Kits for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 4001.002583).
	C58	Co-pending Application Serial No. 09/561,108; Entitled: "Antibody Conjugate Compositions for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 3999.002584).
	C59	Co-pending Application Serial No. 09/561,526; Entitled: "Antibody Conjugate Kits for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 3999.002586).

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)	Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Thorpe and Brekken	
	Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C60	Deonarain and Epenetos, "Targeting Enzymes for Cancer Therapy: Old Enzymes in New Roles," <i>Br. J. Cancer</i> , 70(5):786-794, 1994.
	C61	Giorgio <i>et al.</i> , "Ellipticine Conjugated to Anti VEGFR2 Monoclonal Antibodies as Reagents for Targeting angiogenesis," <i>Proc. Amer. Assoc. Can. Ann.</i> , 41:387, 2000.
	C62	Haisma <i>et al.</i> , "Analysis of a Conjugate between Anti-Carcinoembryonic Antigen Monoclonal Antibody and Alkaline Phosphatase for specific Activation of the Prodrug Etoposide Phosphate," <i>Cancer Immunol. Immunother.</i> , 34(5):343-348, 1992.
	C63	Huber <i>et al.</i> , "Vascular Endothelial Growth Factor Receptor (VEGFR-2) Antibody Therapy Combined with Conventional Chemotherapy Inhibits Growth of Established Tumors in Mice," <i>Proc. Amer. Assoc. Cancer Res. Ann.</i> , 41:567, 2000.
	C64	Muller <i>et al.</i> , "Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site," <i>Proc. Natl. Acad. Sci. USA</i> , 94(14):7192-7197, 1997.
	C65	Ortega <i>et al.</i> , "Signal Relays in the VEGF System," <i>Frontiers in Bioscience</i> , 4:D141-152, 1999.
	C66	Witte <i>et al.</i> , "Monoclonal Antibodies Targeting the VEGF Receptor-2 (Flk1/KDR) as an Anti-Angiogenic Therapeutic Strategy," <i>Cancer and Metastasis Reviews</i> , 17(2):155-161, 1998.
	C67	International Search Report for PCT/US00/11367, mailed October 19, 2000.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Thorpe and Brekken	
	Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A25	5,521,073	05.28.96	Davis <i>et al.</i>	435	69.5	
	A26	5,643,755	07.01.97	Davis <i>et al.</i>	435	69.5	
	A27	5,650,490	07.22.97	Davis <i>et al.</i>	530	350	
	A28	5,814,464	09.29.98	Davis <i>et al.</i>	435	69.5	
	A29	5,851,797	12.22.98	Valenzuela <i>et al.</i>	435	69.1	
	A30	5,879,672	03.09.99	Davis <i>et al.</i>	424	85.1	
	A31	5,972,338	10.26.99	Godowski <i>et al.</i>	424	185.1	
	A32	6,030,831	02.29.00	Godowski <i>et al.</i>	435	320.1	
	A33	6,057,435	05.02.00	Godowski <i>et al.</i>	536	23.5	
	A34	6,074,873	06.13.00	Fong <i>et al.</i>	435	325	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
----------------	--------------	--------------------	------	------	-------	--------------	------------------------

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Kuby, "Antigens", <i>Immunology, Second Edition, Chapter 4</i> , 85-96, 1994.
	C69	Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A35	5,354,778	October 11, 1994	Ray <i>et al.</i>	514	592	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C70	Heimbrook <i>et al.</i> , "Transforming growth factor α - <i>Pseudomonas</i> exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4697-4701, 1990.
	C71	Hirota <i>et al.</i> , "Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody," <i>Cancer Research</i> , 49:7106-7109, 1989.
	C72	Plate <i>et al.</i> , "Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis," <i>Cancer Research</i> , 53(23):5822-5827, 1993.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Dat of App.
	A36	5,786,344	July 28, 1998	Ratain et al.	514	100	
	A37	5,561,122	October 1, 1996	Pettit	514	130	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B6	WO 95/21868	August 17, 1995	PCT			
	B7	WO 94/11499	May 26, 1994	PCT			
	B8	WO 94/10202	May 11, 1994	PCT			
	B9	WO 92/14748	September 3, 1992	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket N . 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B10	WO 93/08210	April 29, 1993	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C73	Denekamp, "Endothelial Cell Attack as a Novel Approach to Cancer Therapy," <i>Cancer Topics</i> , 6:6-8, 1986.
	C74	Denekamp, The Current Status of Targeting Tumor Vasculature as a Means of Cancer Therapy: An Overview," <i>Int. J. Radiat. Biol.</i> , 60:401-408, 1991.

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)	Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Thorpe and Brekken	
	Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	Supplemental European Search Report for Divisional Application 01125821.7, mailed December 27, 2001.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A38	6,342,221	January 29, 2002	Thorpe & Brekken	424	178.1	
	A39	6,342,219	January 29, 2002	Thorpe & Brekken	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorne and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A40	5,024,834	June 18, 1991	Houston <i>et al.</i>	424	85.91	
	A41	4,981,953	January 1, 1991	Barbieri <i>et al.</i>	530	391	
	A42	4,980,457	December 25, 1990	Jansen <i>et al.</i>	530	391	
	A43	4,958,009	September 18, 1990	Bjorn <i>et al.</i>	530	389	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B11	WO 91/07941	June 13, 1991	PCT			
	B12	EP 0 255 424 A1	February 3, 1988	EPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A44	6,291,667	Sept. 18, 2001	Gill <i>et al.</i>	536	24.5	
	A45	6,121,230	Sept. 19, 2000	Charnock-Jones <i>et al.</i>	514	2	
	A46	6,024,955	Feb. 15, 2000	Asano <i>et al.</i>	424	130.1	
	A47	6,020,473	Feb. 01, 2000	Keyt <i>et al.</i>	536	23.1	
	A48	6,008,319	Dec. 28, 1999	Epstein <i>et al.</i>	530	324	
	A49	6,007,817	Dec. 28, 1999	Epstein <i>et al.</i>	424	178.1	
	A50	5,942,385	Aug. 24, 1999	Hirth	435	4	
	A51	5,730,977	March 24, 1998	Ooka <i>et al.</i>	424	141.1	
	A52	5,240,848	Aug. 31, 1993	Keck <i>et al.</i>	537	240.2	
	A53	5,036,003	July 30, 1991	Olander <i>et al.</i>	435	70.1	
	A54	5,008,196	April 16, 1991	Connolly <i>et al.</i>	435	240.2	
	A55	2002/0032315	March 14, 2002	Baca <i>et al.</i>	530	388.23	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B13	EP 0 666 868 B1	April 03, 2002	EPO			
	B14	WO 00/37502	June 29, 2000	PCT			
	B15	WO 00/34337	June 15, 2000	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1644
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A56	6,416,758	July 9, 2002	Thorpe <i>et al.</i>	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A57	6,180,370	January 30, 2001	Queen <i>et al.</i>	435	69.6	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C76	Bodey <i>et al.</i> , "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Res.</i> , 20:2665-2676, 2000.
	C77	Colman, "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions," <i>In A Structural View of Immune Recognition by Antibodies</i> , 33-36, 1994.
	C78	Spitler, "Cancer Vaccines: The Interferon Analogy," <i>Cancer Biotherapy</i> , 10(1):1-3, 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C79	Abaza and Atassi, "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <i>J. Protein Chemistry</i> , 11(5):433-444, 1992
	C80	Attwood, "The Babel of Bioinformatics," <i>Science</i> , 290(5491):471-473, 2000.
	C81	Mikayama <i>et al.</i> , "Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor," <i>Proc. Natl. Acad. Sci. USA</i> , 90:10056-10060, 1993.
	C82	Ngo <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>In, The Protein Folding Problem and Tertiary Structure Prediction</i> , Eds., Merz & LeGrand, pp. 492-495, 1994.
	C83	Voet <i>et al.</i> , "Chemical Evolution," <i>In, Biochemistry I</i> , Voet & Voet, pp. 126-234, 1990.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C84	Connolly <i>et al.</i> , "Human Vascular Permeability Factor," <i>J. Biol. Chem.</i> , 264(33):20017-20024, 1989.
	C85	Ferrara <i>et al.</i> , "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins," <i>Endocrine reviews</i> , 13(1):18-32, 1992.
	C86	Hori <i>et al.</i> , "Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblast Growth Factor," <i>Cancer Res.</i> , 51:6180-6184, 1991.
	C87	Takahashi <i>et al.</i> , "Inhibition of Cell Growth and Tumorigenesis of Human Glioblastoma Cells by a Neutralizing Antibody Against Human Basic Fibroblast Growth Factor," <i>FEBS Lett.</i> , 288(1,2):65-71, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A58	6,524,583	February 25, 2003	Thorpe <i>et al.</i>	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.